Thin
Direct API manufacturing solutions engineered for formulation developers in Colombo, Kandy, and regional pharmaceutical clusters seeking commercial supply continuity.
A critical shift is unfolding across the Indian Ocean basin: transitioning from reliance on expensive imported finished dosage pens toward local formulation and regulatory self-reliance.
Sri Lanka stands at a pivotal intersection in public health and industrial pharmaceutical policy. Type 2 diabetes mellitus (T2DM) and obesity-driven metabolic syndromes present an escalating clinical challenge across both urban centers like Colombo and rural provinces. Epidemiological records demonstrate that urban adult diabetes prevalence exceeds 20%, intensifying demand for advanced therapeutic options that can deliver glycemic equilibrium, cardioprotection, and sustained weight management.
Historically, the National Medicines Regulatory Authority (NMRA) of Sri Lanka and the State Pharmaceuticals Corporation (SPC) have depended primarily on finished dosage forms imported from multinational conglomerates. However, the associated foreign exchange volatility and retail price premiums of branded GLP-1 pens have restricted accessibility, leaving significant patient segments without adequate long-term therapy.
In response, leading Sri Lankan drug manufacturers and compounding facilities located within designated pharmaceutical manufacturing zones—such as the Oyamaduwa Pharmaceutical Zone in Anuradhapura and Arabokka in Hambantota—are rapidly developing internal sterile fill-finish capabilities. Their strategic objective is clear: source ultra-pure Active Pharmaceutical Ingredients (APIs) directly from cGMP-certified multi-ton synthesis bases to produce affordable, generic pre-filled pens, multi-dose vials, and oral peptides.
Our peptide APIs are accompanied by full Common Technical Document (CTD) format documentation, including detailed synthesis routes, residual solvent analysis, host-cell protein monitoring, and real-time ICH Q1A(R2) stability profiles suitable for direct NMRA submission in Sri Lanka.
Understanding the synthesis barriers, orthogonal side-chain protection schemes, and purification architectures critical to preventing diastereomers and deletion sequences.
By employing automated microwave-assisted continuous flow solid-phase synthesis, coupling cycles for sterically hindered sequences (such as Aib8 in Semaglutide) achieve completion rates exceeding 99.8%, effectively eliminating [des-Aib8] impurities.
GLP-1 analogues requiring side-chain acylation (e.g., C18 diacid or C20 diacid fatty chains linked via γ-Glu-AEEA spacers) undergo chemoselective deprotection without inducing racemization at adjacent chiral centers.
Two-tier reversed-phase high-performance liquid chromatography using dynamic axial compression (DAC) columns separates critical pairs (D-stereoisomers and β-aspartyl shifts) to ensure bulk API purity consistently exceeds 99.0%.
| Analytical Parameter | Thinheal Commercial Release Standard | Generic Pharmacopeial Benchmark | Significance for Sri Lankan Formulators |
|---|---|---|---|
| HPLC Chromatographic Purity | ≥ 99.0% (Single Max Impurity ≤ 0.5%) | ≥ 97.5% (Single Max Impurity ≤ 1.0%) | Minimizes immunogenicity in multi-dose subcutaneous therapies. |
| Bacterial Endotoxin Levels | < 0.05 EU/mg (LAL Chromogenic Assay) | < 5.0 EU/mg | Protects against pyrogenic reactions during clinical batch reconstitution. |
| Residual Organic Solvents | ICH Q3C Class 2/3 limits (GC-HS verified) | Standard compendial limits | Complies with NMRA environmental and toxicological regulations. |
| Counter-Ion Distribution | Acetate Content 3.0% - 10.0% (TFA < 0.1%) | Uncontrolled TFA trace allowed | Prevents local site irritation and enhances formulation shelf-life. |
| Aggregation & High Mol Wt Impurities | < 0.2% (SE-HPLC analysis) | < 1.0% | Essential for maintaining aqueous stability inside multi-use cartridge pens. |
Sri Lanka’s tropical maritime climate—characterized by ambient temperatures often surpassing 30°C and relative humidity exceeding 80%—demands specialized cold-chain infrastructure for peptide cargo.
Shipments destined for Bandaranaike International Airport (CMB) utilize vacuum insulated panels (VIP) and validated dry ice / phase-change material (PCM) shippers maintaining constant -20°C or 2-8°C across 96 continuous hours.
Our dedicated Asia Desk prepares pre-cleared shipping dossiers including import permits, air waybills, dangerous goods declarations (if applicable), and notarized batch Certificates of Analysis to eliminate dwell times at Colombo customs.
Beyond API shipping, our formulation science liaisons provide Sri Lankan manufacturers with reconstitution protocols, phenolic preservative compatibility data, and lyophilization cycle optimization services.
Complementing our core metabolic series, these high-barrier peptide drug substances support diversified manufacturing across neuroprotection, immunology, and regenerative medicine in Sri Lanka.
Essential guidance for sourcing directors, quality heads, and import managers evaluating peptide suppliers for clinical trials and commercialization.
Each delivery includes a lot-specific Certificate of Analysis (CoA) documenting HPLC purity, mass spectrometry (LC-MS) molecular mass identity, residual solvents via GC-HS, bacterial endotoxin counts, bioburden, and specific optical rotation. We also supply DMF technical documentation formatted to support NMRA product registration dossiers.
Peptide APIs are lyophilized into high-stability amorphous powders and packed in amber borosilicate type-I vials under an argon blanket. We ship in certified temperature-monitored shippers (using NIST-traceable single-use USB data loggers) maintaining either -20°C or 2-8°C to withstand tropical ambient conditions throughout customs clearance in Sri Lanka.
Yes. While generic chemical synthesis often produces peptides containing trifluoroacetic acid (TFA) salts, our multi-ton purification infrastructure offers controlled acetate or hydrochloride salt exchanges, maintaining residual TFA below 0.1% to align with parenteral formulation requirements in Sri Lanka.
We accommodate clinical development pipelines starting from 10g to 100g pilot evaluation batches up to multi-kilogram commercial campaigns. Catalog GLP-1 analogues like Semaglutide and Tirzepatide typically ship within 5 to 7 business days from warehouse inventory, while custom sequence synthesis requires 3 to 6 weeks.